The Technical Analyst
Co-Diagnostics Inc [CODX]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Co-Diagnostics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.86% $1.150
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 35.95 mill |
| EPS: | -1.200 |
| P/E: | -0.960 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 31.26 mill |
| Avg Daily Volume: | 0.0582 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.960 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.960 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0835 (-92.74%) $-1.066 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.088 - 1.212 ( +/- 5.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Abbott Richard David | Buy | 0 | Common Stock |
| 2024-03-15 | Abbott Richard David | Buy | 0 | Common Stock |
| 2024-03-15 | Abbott Richard David | Buy | 83 251 | Common Stock Purchase Warrants |
| 2024-03-15 | Abbott Richard David | Sell | 50 438 | Restricted Stock Units |
| 2023-11-23 | Durenard Eugene | Sell | 30 000 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| 27.39 |
| Last 96 transactions |
| Buy: 3 281 333 | Sell: 1 334 875 |
Forecast:
16:00 - $1.155
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.155
Forecast 2: 16:00 - $1.155
Forecast 3: 16:00 - $1.155
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.150 (-0.86% ) |
| Volume | 0.0184 mill |
| Avg. Vol. | 0.0582 mill |
| % of Avg. Vol | 31.63 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CODX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Latest Press Releases
2024-04-12 09:30:00 - Press Release
Co-diagnostics, Inc. Inaugurates New Manufacturing Facility In Utah With Ribbon Cutting Event
Ribbon-cutting included support from mayor wood of south salt lake and other dignitaries salt lake city , april 12, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it held the ribbon cutting event for its new manufacturing facility yesterday in the city of south salt lake. the facility has been designed to manufacture the co-dx pro™ instrument and test cups for the new platform*, as well as the company's patented co-primers™ chemistry that underpins the company's pcr diagnostic tests.
2024-04-04 09:30:00 - Press Release
Co-diagnostics, Inc. Appoints New President And Other C-level Positions
Salt lake city , april 4, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) ("co-dx™" or the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the board of directors appointed richard abbott as president of co-diagnostics, inc., concurrent with the company naming david nielsen to be its chief operations officer (coo), christopher thurston as its chief technology officer (cto), and seth egan as chief commercialization officer (cco). prior to his new role at the company, richard abbott (president) served as the president of advanced conceptions, inc., a wholly-owned subsidiary of co-diagnostics since december 2021, and has been instrumental in establishing the teams and technology of the co-dx pcr platform*.
2024-03-21 09:30:00 - Press Release
Co-diagnostics, Inc. Ceo Delivers Manufacturing And Commercialization Update In Conference Keynote Address
Presentation included announcement of the opening of the new manufacturing facility in salt lake city, ut salt lake city, march 21, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address at the 5th annual marketsandmarkets conference in london, company ceo dwight egan shared an update on the new manufacturing facilities in salt lake city, utah and in ranoli, india, including announcing the grand opening of the new utah facility next month. both co-dx and cosara diagnostics, the company's joint venture for manufacturing in india, will be manufacturing the co-dx™ pcr pro™ instrument and co-dx pcr test cups that run on the company's new pcr platform*.
2024-03-18 09:30:00 - Press Release
Co-diagnostics, Inc. Ceo To Deliver Keynote Address At Marketsandmarkets 2024 In London, England
Salt lake city, utah , march 18, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that co-dx ceo dwight egan will deliver the keynote address at the 5th annual infectious disease diagnostics and molecular diagnostics conference, organized by marketsandmarkets and held march 21-22, 2024, in london, england. mr. egan will be delivering the keynote presentation at 9:00 am local time on march 21, and will be discussing impacts that the company's upcoming co-dx pcr platform* is anticipated to have on the future of diagnostics accessibility.
2024-03-14 16:01:00 - Press Release
Co-diagnostics, Inc. Reports Full Year 2023 Financial Results
Salt lake city , march 14, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended december 31, 2023. full year 2023 financial results: revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the logix smart® covid-19 tests.
Latest News
2024-03-14 21:19:11 - Seeking Alpha
Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript
2024-02-29 09:30:00 - PRNewsWire
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast
SALT LAKE CITY , Feb. 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2023 financial results on Thursday, March 14, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
2023-11-09 19:59:09 - Seeking Alpha
Co-Diagnostics, Inc. (CODX) Q3 2023 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Hello. Welcome to the Co-Diagnostics Third Quarter 2023 Earnings Conference Call.
2023-10-26 09:30:00 - PRNewsWire
Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast
SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2023 results on Thursday, November 9, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
2023-08-10 18:16:13 - Zacks Investment Research
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.10 per share a year ago.
2023-07-27 09:30:00 - PRNewsWire
Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast
SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2023 results on Thursday, August 10, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
2023-05-11 22:33:08 - Seeking Alpha
Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Theodore O'Neill - Litchfield Hills Research Operator Good afternoon and welcome to the Co-Diagnostics' First Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded today.
2023-05-11 19:02:45 - Zacks Investment Research
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.26 per share a year ago.
2023-03-16 19:05:47 - Zacks Investment Research
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-16 18:37:05 - Seeking Alpha
Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, President and Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Theodore O'Neill - Litchfield Hills Research Operator Good afternoon, and welcome to the Co-Diagnostics, Inc. Fourth Quarter and Full Year 2022 Earnings Results Conference Call.